The Patent Finder

Terms ending in 2037

Atea Pharmaceuticals, Inc.

Every in-force patent on Atea Pharmaceuticals, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,202,412BETA-D-2'-Deoxy-2'-Substituted-4'-Substituted-2-Substituted-N6-SUBSTITUTED-6-Aminopurinenucleotides for the Treatment of Paramyxovirus and Orthomyxovirus Infections
In force
 · Medium confidence
Atea Pharmaceuticals, Inc.In forceMedium confidence
US 10,711,029BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-4'-Fluoro-N6-SUBSTITUTED-6-Amino-2-Substituted Purine Nucleotides for the Treatment of Hepatitis C Virus Infection
In force
 · High confidence
Atea Pharmaceuticals, Inc.In forceHigh confidence
US 10,946,0332'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
In force
 · Medium confidence
Atea Pharmaceuticals, Inc.In forceMedium confidence
US 11,975,0162'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
In force
 · Low confidence
Atea Pharmaceuticals, Inc.In forceLow confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited